Discover key takeaways from Nabors Industries' Q3 2025 earnings: debt reduction, international growth, EBITDA trends, and strategic insights.

Savara Inc. (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has commenced an underwritten public offering of shares of its ...

Discover Q3 2025 highlights for Central Pacific Financial Corp.: earnings growth, margin expansion, and a new Japan partnership.